ArticleJournal of inflammation research2026
Identification of Immune-Inflammatory Endotypes in Early COPD Risk: A Cluster Analysis of Age-Associated Biomarkers.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is increasingly recognized as a highly heterogeneous syndrome rather than a single disease entity. Identifying biologically distinct endotypes is essential for early risk stratification and precision prevention. Immunosenescence-the age-related remodeling of the immune system-has been associated with COPD pathogenesis, but its heterogeneity remains poorly characterized. Methods: We employed a two-stage discovery‑validation design. The discovery cohort included 439 healthy adults (2019-2020), in whom age‑associated immune biomarkers were identified using Spearman correlation. The validation cohort comprised 89 community‑dwelling adults (2023-2024), including 34 healthy controls and 55 individuals at high risk for COPD (COPD‑SQ ≥ 16, preserved lung function). Biomarkers that were both age‑associated and differentially expressed between groups were selected for further analysis. To investigate the inherent heterogeneity of immune‑inflammatory profiles, we performed unsupervised k‑means clustering and principal component analysis (PCA) on these selected biomarkers in the validation cohort. The association between cluster membership and COPD high‑risk status was assessed using logistic regression. Results: Four cytokines (IL‑4, IL‑5, IL‑6, IL‑12p70) were significantly correlated with age and differentially elevated in the high‑risk group. Unsupervised clustering identified three distinct immune‑inflammatory endotypes: a high‑inflammatory endotype (n = 13, 100% high‑risk), a moderate‑inflammatory endotype (n = 29, 89.7% high‑risk), and a low‑inflammatory endotype (n = 45, 35.6% high‑risk). Using the low‑inflammatory endotype as reference, both high‑inflammatory (unadjusted Conclusion: This study identifies three distinct immune‑inflammatory endotypes in a community‑based population at risk for COPD, with the high‑ and moderate‑inflammatory endotypes showing strong, independent associations with high‑risk status. These findings reveal the biological heterogeneity of immunosenescence and provide a framework for endotype‑based risk stratification in early COPD. The results highlight the potential of cluster‑derived immune profiles to inform targeted prevention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.